| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Nicola Silvestris | Q87916808 |
| Marc Peeters | Q38324454 | ||
| Christian Rolfo | Q51069805 | ||
| Domenico Ribatti | Q59681775 | ||
| Oronzo Brunetti | Q39379387 | ||
| Eugenio Maiorano | Q43298248 | ||
| Antonio Russo | Q46653000 | ||
| P2093 | author name string | Mario Testini | |
| Aldo Scarpa | |||
| Luigi Lupo | |||
| Vito Longo | |||
| Amalia Azzariti | |||
| Valeria Simone | |||
| Michele Simone | |||
| P2860 | cites work | Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 |
| Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma | Q84792092 | ||
| Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q88406073 | ||
| Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation | Q22004269 | ||
| Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors | Q26773795 | ||
| Cholangiocarcinoma: Current Knowledge and New Developments | Q28076098 | ||
| Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis | Q28216758 | ||
| Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update | Q28273143 | ||
| Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes | Q29547633 | ||
| Tumorigenesis and the angiogenic switch | Q29619849 | ||
| Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data | Q31033443 | ||
| A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study | Q33398787 | ||
| Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma | Q33605089 | ||
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial | Q33620083 | ||
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study | Q34048813 | ||
| Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 | ||
| Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis | Q34344162 | ||
| Vascular endothelial growth factor: basic science and clinical progress | Q34549887 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Clinical diagnosis and staging of cholangiocarcinoma | Q34631337 | ||
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers | Q35023456 | ||
| FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | Q35078039 | ||
| Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways | Q35190775 | ||
| Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma | Q35629462 | ||
| HCC and angiogenesis: possible targets and future directions | Q35698574 | ||
| Tumor necrosis factor-α promotes the lymphangiogenesis of gallbladder carcinoma through nuclear factor-κB-mediated upregulation of vascular endothelial growth factor-C. | Q35713318 | ||
| Nuclear factor-kappaB: the enemy within | Q35893620 | ||
| Prognostic significance of microRNA-203 in cholangiocarcinoma | Q36095393 | ||
| Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis | Q36111400 | ||
| HIF-1α pathway: role, regulation and intervention for cancer therapy | Q36238647 | ||
| Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma | Q36245788 | ||
| Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial | Q36287599 | ||
| SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma | Q36376264 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers | Q36677934 | ||
| Tumour-associated angiogenesis in human colorectal cancer. | Q36689348 | ||
| Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes | Q36759538 | ||
| Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells | Q36822722 | ||
| A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. | Q37111209 | ||
| Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma | Q37177871 | ||
| Drug resistance associated with antiangiogenesis therapy | Q37518288 | ||
| Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. | Q37588461 | ||
| S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma | Q37594373 | ||
| Role of tumour-associated macrophages in cancer-related inflammation | Q37853003 | ||
| CD146, a multi-functional molecule beyond adhesion | Q38069744 | ||
| Histamine and histamine receptor regulation of gastrointestinal cancers | Q38196813 | ||
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma | Q38200403 | ||
| Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis | Q38208583 | ||
| Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment | Q38216461 | ||
| Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis | Q38290076 | ||
| Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma | Q38804116 | ||
| YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. | Q50577910 | ||
| Genomic spectra of biliary tract cancer. | Q53390123 | ||
| Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation | Q58450934 | ||
| Tumor induction of VEGF promoter activity in stromal cells | Q77349243 | ||
| Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis | Q77668037 | ||
| Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas | Q78204868 | ||
| Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance | Q82499254 | ||
| Microvessel density correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma | Q83080823 | ||
| Lymphangiogenic and angiogentic microvessel density in gallbladder carcinoma | Q83923681 | ||
| Inhibition of tumor angiogenesis by interferon-γ by suppression of tumor-associated macrophage differentiation. | Q38992520 | ||
| Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma | Q39001956 | ||
| Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo. | Q39017898 | ||
| miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). | Q39162380 | ||
| Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma | Q39179249 | ||
| Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma | Q39325255 | ||
| Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer | Q39445782 | ||
| Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells | Q39589946 | ||
| Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. | Q39693531 | ||
| H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. | Q39787871 | ||
| Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy | Q39995898 | ||
| Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis | Q40582589 | ||
| A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model | Q40636256 | ||
| A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study | Q41652822 | ||
| Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment | Q42029380 | ||
| The prometastatic microenvironment of the liver | Q42203607 | ||
| VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells | Q42815794 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma | Q43846474 | ||
| Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis | Q44602053 | ||
| Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas | Q44660500 | ||
| Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas | Q44911533 | ||
| Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers | Q45704144 | ||
| Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase | Q46301097 | ||
| Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme | Q48058166 | ||
| Expressions of VEGF-C and VEGF-D and their correlation with lymphangiogenesis and angiogenesis in gallbladder carcinoma | Q50151361 | ||
| Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma | Q50176110 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| angiogenesis inhibitor | Q574834 | ||
| neovascularization | Q1281049 | ||
| biliary tract neoplasm | Q18553364 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-02-15 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option | |
| P478 | volume | 18 |
| Q95843571 | A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer |
| Q99580546 | A review of systemic therapy in biliary tract carcinoma |
| Q58605334 | Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell |
| Q90411340 | Application of Laparoscopic Radical Resection for Type III and IV Hilar Cholangiocarcinoma Treatment |
| Q89835342 | Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models |
| Q50129481 | Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo |
| Q38654867 | The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. |
| Q99352179 | Therapy of Primary Liver Cancer |
| Q47169336 | Tumor Microenvironment and Metabolism. |
Search more.